• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Heliyon . Development and application of an RT‒PCR assay for the identification of the delta and omicron variants of SARS-COV-2

tetano

Editor, Senior Moderator
Heliyon


. 2023 Jun;9(6):e16917.
doi: 10.1016/j.heliyon.2023.e16917. Epub 2023 Jun 1. Development and application of an RT‒PCR assay for the identification of the delta and omicron variants of SARS-COV-2

G A Shipulin[SUP] 1 [/SUP], YuA Savochkina[SUP] 1 [/SUP], A K Shuryaeva[SUP] 1 [/SUP], E E Glushchenko[SUP] 1 [/SUP], A R Luparev[SUP] 1 [/SUP], V A Polyakova[SUP] 1 [/SUP], D I Danilov[SUP] 1 [/SUP], E E Davydova[SUP] 1 [/SUP], K S Vinogradov[SUP] 1 [/SUP], I F Stetsenko[SUP] 1 [/SUP], A A Aiginin[SUP] 1 [/SUP], A D Matsvay[SUP] 1 [/SUP], K B Kolbutova[SUP] 2 [/SUP], S A Bogdan[SUP] 2 [/SUP], M A Vashukova[SUP] 3 [/SUP], S M Yudin[SUP] 1 [/SUP]



Affiliations
Abstract

The emergence of mutations in the coronavirus genome provides opportunities for occurrence new strains with higher transmissibility, severity and duration of the disease poses. In 2020, a new variant of the coronavirus SARS-COV-2 - Delta was identified in India. This genetic variant has spread rapidly and became dominant in many countries, including Russia. In November 2021, a new outbreak of COVID-19 occurred in Africa driven by a variant SARS-COV-2 named later Omicron. Both variants had increased transmissibility compared to previously encountered variants and quickly, replacing its around the world. To promptly monitor the epidemiological situation in the country, to assess the spread of dominant genetic variants of the virus and to take appropriate measures, we have developed an RT‒PCR reagent kit for the identification of Delta and Omicron by detecting a corresponding combination of major mutations. The minimum set of mutations was chosen which allows to differentiate Delta and Omicron variants, in order to increase the analysis productivity and reduce costs. Primers and LNA-modified probes were selected to detect mutations in the S gene, typical for the Delta and Omicron. Similar approach can be implemented for the rapid development of assays for differentiating important SARS-COV-2 variants or for other viruses genotyping for epidemiological surveillance or for diagnostic use in order to assist in making clinical decisions. It was demonstrated that the results of VOC Delta and Omicron detection and their typical mutations were concordant with genotyping based on WGS results for all 847 samples of SARS-CoV-2 RNA. The kit has high analytical sensitivity (1х10[SUP]3[/SUP] copies/mL of SARS-CoV-2 RNA) for each of the detected genetic variants and possesses 100% analytic specificity for microorganism panel testing. The diagnostic sensitivity (95% confidence interval) obtained during pivotal trials was 91.1-100% for Omicron and 91.3-100% for Delta, while the diagnostic specificity with a 95% confidence interval was 92.2-100%. The use of a set of reagents in combination with sequencing of SARS-CoV-2 RNA as part of epidemiological monitoring made it possible to quickly track the dynamics of changes in Delta and Omicron prevalence in the Moscow region in the period from December 2021 to July 2022.

Keywords: COVID-19; Coronavirus; Delta; Omicron; RT-PCR; SARS-COV-2; Variant of concern.

 
Back
Top Bottom